Dupilumab - CAS 1190264-60-8
Dupilumab (CAT: I017509) is a monoclonal antibody used for the treatment of certain inflammatory conditions, specifically moderate-to-severe atopic dermatitis (eczema) and moderate-to-severe asthma. It works by targeting and inhibiting the interleukin-4 receptor alpha (IL-4Rα), which plays a key role in the immune system’s response to allergic and autoimmune diseases. By blocking IL-4Rα, dupilumab helps reduce inflammation and associated symptoms in patients with atopic dermatitis and asthma. It has demonstrated efficacy in improving skin lesions and reducing the need for topical corticosteroids in eczema patients.
* For research use only. Not for human or veterinary use.